← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 5.2% to $1.22B, while Net income decreased 56.3% to $73.4M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $1.22BOK
- Profitability — Net income $73.4MOK
- Cash generation — Free cash flow $256.6MOK
- Accounting — Formula-grey distress score · no manipulation flag · earnings quality safeNote
- Insiders — 0 buys; 3 sells in 365 daysNote
- Capital — dividends paid were $50.4M; share repurchases were $275.7MNote
Business
BIO-TECHNE Corp: BUSINESS OVERVIEW Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide.
Where the revenue comes from
Fiscal 2025, as BIO-TECHNE Corp reports it. History and quarterly detail are in the app.
- Protein Sciences$870.2M
- Diagnostics And Spatial Biology$346.3M
- All Other Segments$4.2M
Leadership changes
From BIO-TECHNE Corp's own filings, the day they're filed.
- Becton Dickinson · Chief Executive Officer · departureeff. 2024-02-01
- Judith Klimovsky · director · appointment
- Roeland Nusse · Directors · departure
Latest filings
- 10-K · Annual report2026-08-24
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-06-25
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIO-TECHNE Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.